(My thanks to David Armstrong, DPM, PhD for bringing this press release to my attention) TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing in Diabetic Foot Infection Met Primary Endpoints According to its manufacturer TaiGen, nemonoxacin, a novel, non-fluorinated quinolone has shown promising results in a single armed, multinational, proof of concept Phase II clinical trial … Read more
For a number of years I have been presenting a lecture entitled “Differentiating infected from non-infected wounds”. As part of that talk I discuss the role of topical antimicrobials in wound healing. Despite there being a countless number of silver impregnated dressings along with multiple other antimicrobial dressings and solutions filled with all different types … Read more
One of our readers recently sent the blog the following comment: “Anything new to add to comments in book about laser treatment of fungal nails? In my area there are ads for DPMs offering this $1000 per treatment! My question is; does it work?” Up to this point I have been tacitly avoiding this topic … Read more
To any of my readers planning on attending the NY Clinical Conference this coming weekend, I will be in the exhibit hall at the DataTrace booth on Saturday January 30th. I will be there to discuss this blog, sign copies of the 3rd Edition (not that it will increase the value of it…heck, it may … Read more
Two studies published in the January 7, 2010 issue of the New England Journal of Medicine have received a tremendous amount of play in the popular press. One paper out of Baylor in Houston looked at comparing chlorhexidine + alcohol vs. povidone iodine as a preoperative surgical prep. In a total of 849 subjects in … Read more
Telavancin (Vibativ – Theravance/Astellas) is a novel lipoglycopeptide, related to vancomycin, that has been recently approved by the FDA for the treatment of complicated skin and skin structure infections (cSSSI) caused by MRSA. Telavancin now joins the ranks of vancomycin, linezolid, daptomycin and tigecycline as being the only 5 antibiotics with this approval. An excellent … Read more
Some interesting news just came out yesterday. It looks like J&J’s new anti-MRSA cephalosporin, ceftobiprole has been, once again, turned back by the FDA. See the story here: http://money.cnn.com/news/newsfeeds/articles/marketwire/0572888.htm Many of us had pretty high hopes for this antibiotic as it was to be the first cephalosporin active against MRSA. Although it is IV only, … Read more
On Barry Block’s daily PM News (www.podiatrym.com) the other day a colleague presented a case of a neuropathic patient with no wounds presenting with what he felt was osteomyelitis of the 2nd and 3rd metatarsals. Although I did not feel that the case was actually osteomyelitis, a feeling I expressed in a response to that … Read more
Dr. Todd Divan, a podiatric physician from Potomac, IL, sent me an excellent question via personal email. On the belief that if one person asks a question, many others may be thinking the same thing, I reprint the question and answer here with Dr. Divan’s kind permission. Dr. Joseph, I listened to the lecture you … Read more
One of the ideas behind creating this blog was to be able to keep readers apprised of any new, interesting papers published in the infectious diseases and microbiology literature I follow on a regular basis. For background I will tell you that my 3 top journals include: Clinical Infectious Diseases (CID) – put out by … Read more